Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

LEGO

Financiado

Cerrado

Multimodal glycoconjugates a molecular Lego approach for antitumoral immunother...

Multimodal glycoconjugates a molecular Lego approach for antitumoral immunotherapy Despite significant progress in cancer therapy, current treatments are still controversial due to intolerable side effects. Targeted immunotherapy has recently emerged as an ideal alternative to improve treatment modalities for ca... ver más

28/02/2021

UGA

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

UNIVERSITE GRENOBLE ALPES No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 3 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2021-02-28

ERC-CoG-2014: ERC Consolidator Grant

I+D

Cerrada hace 10 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

3 Participantes

UGA

2.00M€ | Lider

PROGANDO

478.86K€ | Participante

CNRS

53.85K€ | Participante

Proyectos interesantes

RTC-2016-5118-1

Medical Technol...

Biotechnology

313K€ Cerrado

RTC-2017-5944-1

Medical Technol...

Biotechnology

332K€ Cerrado

GlycoTherapy

Medical Technol...

Data Science

2M€ Cerrado

BispecificsThatClick

Medical Technol...

Biotechnology

213K€ Cerrado

DEGLYCAR-T

Medical Technol...

Biotechnology

2M€ Cerrado

SAF2017-89437-P

Medical Technol...

Biotechnology

157K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 67 meses Fecha Inicio: 2015-07-16
Fecha Fin: 2021-02-28

Líder del proyecto

UNIVERSITE GRENOBLE ALPES No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Despite significant progress in cancer therapy, current treatments are still controversial due to intolerable side effects. Targeted immunotherapy has recently emerged as an ideal alternative to improve treatment modalities for cancers patients. However, very limited approaches are available today and major issues remain to be addressed. The ERC grant offers a unique opportunity to propose a new paradigm for treating cancer. Through a ground-breaking interdisciplinary program, at the crossroad of supramolecular chemistry, synthetic chemistry, molecular engineering, biophysics, biochemistry, immunochemistry and glycoscience, it is my ambition to design, synthesize and study smart biomolecular structures with unprecedented combinations, complexity and immunological properties against cancers. To achieve this purpose, I will develop a molecular LEGO approach to construct synthetic molecules capable of redirecting endogenous antibodies present in the human bloodstream against tumors without preliminary immunization. Efficient tumoral killing by immune effectors will be provided by molecules combining innovative antibody and tumor binding modules that will be selected in vitro beforehand. To be successful, I will address fundamental questions that are still unresolved in chemical and biological sciences. The expected breakthroughs will represent a landmark achievement in these fields and will open promising horizons in cancer immunotherapy. Beyond this, it can be expected that our findings will pave the way to future development of synthetic molecules embedded with recognition, labeling, and/or therapeutic functions. They will thus find wider medicinal, diagnostic and even theranostic applications for which the development of more effective and selective biomolecular systems is of the utmost importance.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores